Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information
Captisol® is Ligand Pharmaceuticals' solvent-free, all-aqueous processed modified cyclodextrin that helps you get your product to market and to the patients you serve. We've helped over 13 million patients in 120 countries optimize their drug products.
Captisol® can be used for oral, ophthalmic, nasal, inhalation, and parenteral administration. By significantly improving the solubility, stability, and therefore bioavailability of insoluble ingredients, Captisol® may be the ideal excipient for difficult to formulate compounds. Captisol is not limited to the pharmaceutical industry. It can be used in supplements, personal care, food/beverages, and agriculture around the world.
The scientists at Ligand Pharmaceuticals are experts at working with Captisol®, have developed products in-house and aided clients in developing many successful formulations. Our expertise in navigating chemistry, manufacturing, and controls (CMC), regulatory, and clinical issues is unparalleled in the industry.
We offer unprecedented service to our partners due to our knowledge and competency in developing formulations with cyclodextrins and aided our partners in their development to have these products approved.
